FDA warned Painless Tattoo Cream Co. that its numbing cream and spray are unapproved new drugs with excess lidocaine.
What happened
FDA reviewed the company’s website in November 2023 and found PAINLESS TATTOO NUMBING CREAM and PAINLESS TATTOO NUMBING SPRAY sold as external analgesics for use before, during, and/or after cosmetic procedures. FDA said the labels list lidocaine 5%, above the allowed 0.5% to 4% range, and include prilocaine and epinephrine, which are not permitted in the OTC external analgesic monograph.
What FDA found
The products are unapproved new drugs (drugs sold without the required FDA approval) because they are marketed without an approved application and do not meet the OTC external analgesic rules.
FD&C Act section 505(a), 21 U.S.C. 355(a)The products are misbranded (unlawfully labeled or marketed) because they are nonprescription drugs that do not comply with section 505G and are not covered by an approved application.
FD&C Act section 502(ee), 21 U.S.C. 352(ee)Lidocaine is labeled at 5%, above the 0.5% to 4% range allowed by the OTC external analgesic monograph.
FD&C Act section 505G, 21 U.S.C. 355h; OTC Monograph M017Prilocaine and epinephrine are listed as active ingredients even though the OTC external analgesic monograph does not permit them.
FD&C Act section 505G, 21 U.S.C. 355h; OTC Monograph M017Labeling claims uses for tattooing, piercing, cosmetic procedures, and broken skin that are not allowed indications in the OTC external analgesic monograph.
FD&C Act section 505G, 21 U.S.C. 355h; OTC Monograph M017
What FDA wants
FDA tells the company to notify it in writing within 15 working days of the specific steps taken to address the violations and prevent recurrence, with supporting documents, or to explain any delay and give a completion date.
Who should pay attention
- tattoo and cosmetic procedure studios that use or sell numbing products
- brands and retailers selling topical numbing creams or sprays
- consumers using OTC numbing products on broken skin
This is a summary. Read the original letter on fda.gov.